Get the Stockscreener App
1.49
1.32%
-0.02
Pre-market:
1.56
0.07
+4.70%
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Files FDA Fast Track Application for Breakthrough Eye Pain Drug - StockTitan
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive Investors USA
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks
Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa
OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks
Okyo Pharma Limited Announces OK-101 Officially Assigned USAN : Urcosimod -February 12, 2025 at 07:01 am EST - Marketscreener.com
Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs - StockTitan
OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation - Proactive Investors USA
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright - Defense World
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares -February 03, 2025 at 09:04 am EST - Marketscreener.com
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe - Proactive Investors Australia
OKYO Pharma Announces Chairman and CEO Acquire Shares -January 31, 2025 at 07:00 am EST - Marketscreener.com
OKYO Pharma insiders buy shares amid clinical trials - MSN
OKYO Pharma insiders acquire shares - Proactive Investors USA
OKYO Pharma insiders buy shares amid clinical trials By Investing.com - Investing.com South Africa
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence - TipRanks
OKYO Pharma Announces Chairman and CEO Acquire Shares - The Manila Times
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):